冠心病患者行冠状动脉介入术后采用二甲双胍治疗降低心血管事件及冠状动脉支架内再狭窄发生率的影响  

Effect of Metformin on Reducing the Incidence of Cardiovascular Events and Coronary In-Stent Restenosis after Coronary Intervention in Patients with Coronary Heart Disease

作　　者：方勇[1] 芦伟 闫宇 FANG Yong;LU Wei;YAN Yu(General Hospital of Wanbei Coal and Electricity Group,Anhui Suzhou 234000,China)

机构地区：[1]皖北煤电集团总医院心内一科,安徽宿州234000

出　　处：《河北医学》2023年第4期612-616,共5页Hebei Medicine

基　　金：安徽省科技攻关计划资助项目,(编号:1905a0802091)。

摘　　要：目的:探讨二甲双胍治疗接受冠状动脉介入术的冠心病患者对患者冠状动脉支架内再狭窄及心血管事件发生率的影响。方法:回顾性选取2020年2月至2022年2月皖北煤电集团总医院接受冠状动脉介入术治疗的冠心病患者50例,依据术后治疗方法分为二甲双胍组(常规治疗基础上加用二甲双胍)和常规治疗组两组,各25例。对比分析两组患者的一般资料、实验室指标、心血管事件发生情况、冠状动脉支架内再狭窄发生情况。结果:治疗后,两组患者的血糖、胰岛素抵抗指数、低密度脂蛋白、总胆固醇、内脂素、肿瘤坏死因子-α、超敏C反应蛋白水平均模型低于治疗前(P<0.05),网膜素-1水平均模型高于治疗前(P<0.05)。二甲双胍组患者的血糖、胰岛素抵抗指数、低密度脂蛋白、总胆固醇、内脂素、肿瘤坏死因子-α、超敏C反应蛋白水平均明显低于常规治疗组(P<0.05),网膜素-1水平模型高于常规治疗组(P<0.05)。二甲双胍组患者的心血管事件发生率8.00%(2/25)明显低于常规治疗组32.00%(8/25)(χ^(2)=4.500,P<0.05)。二甲双胍组患者的冠状动脉支架内再狭窄发生率12.00%(3/25)明显低于常规治疗组36.00%(9/25)(χ^(2)=3.947,P<0.05)。结论:在常规治疗基础上加用二甲双胍治疗接受冠状动脉介入术的冠心病患者能够进一步降低患者的血糖、血脂、炎症因子和脂肪因子水平,降低冠状动脉支架内再狭窄及心血管事件发生率。Objective:To investigate the effect of metformin on the incidence of in-stent restenosis and cardiovascular events in patients with coronary heart disease who underwent coronary intervention.Methods:From February 2020 to February 2022,50 patients with coronary heart disease who received coronary intervention in Wanbei Coal and Electricity Group General Hospital were selected retrospectively.According to the postoperative treatment methods,they were divided into two groups:metformin group(metformin plus conventional treatment)and conventional treatment group(25 patients in each group).The general information,laboratory indicators,cardiovascular events and in stent restenosis of the two groups were comparatively analyzed.Results:After treatment,the levels of blood glucose,insulin resistance index,low density lipoprotein,total cholesterol,endolipin,tumor necrosis factor-αand hypersensitive C-reactive protein in 2 groups were lower in the model than before treatment(P<0.05),while the levels of omentin-1 in the model were higher than before treatment(P<0.05).The levels of blood glucose,insulin resistance index,low density lipoprotein,total cholesterol,endolipin,tumor necrosis factor-αand hypersensitive C-reactive protein in metformin group were significantly lower than those in conventional treatment group(P<0.05),while the omentin-1 level model was higher than that in conventional treatment group(P<0.05).The incidence of cardiovascular events in metformin group was 8.00%(2/25)lower than that in conventional treatment group 32.00%(8/25)(χ^(2)=4.500,P<0.05).The incidence of coronary restenosis in metformin group was 12.00%(3/25)significantly lower than that in conventional treatment group(36.00%(9/25)(χ^(2)=3.947,P<0.05).Conclusions:The addition of metformin to conventional treatment in patients with coronary heart disease undergoing coronary intervention can further reduce the levels of blood glucose,blood lipid,inflammatory factors and fat factors,and reduce the incidence of coronary stent restenosis and cardiova

关 键 词：冠心病 冠状动脉介入术 二甲双胍 心血管事件 冠状动脉支架内再狭窄 

分 类 号：R541.4[医药卫生—心血管疾病]